Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?

Monica Casiraghi; Juliana Guarize; Alberto Sandri; Patrick Maisonneuve; Daniela Brambilla; Rosalia Romano; Domenico Galetta; Francesco Petrella; Roberto Gasparri; Cesare Gridelli; Filippo De Marinis; Lorenzo Spaggiari

doi:10.1016/j.cllc.2018.10.005

Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?

Monica Casiraghi, Juliana Guarize, Alberto Sandri, Patrick Maisonneuve, Daniela Brambilla, Rosalia Romano, Domenico Galetta, Francesco Petrella, Roberto Gasparri, Cesare Gridelli, Filippo De Marinis, Lorenzo Spaggiari

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

This study aims to analyze the outcome of patients with stage IIIA-N2 non–small-cell lung cancer who underwent pneumonectomy to prove its safety and feasibility, in particular after induction chemotherapy. Based on the acceptable morbidity and mortality rate and the long-term survival, pneumonectomy should not be excluded for selected patients as a matter of principle.

Original language	English
Pages (from-to)	97-106.e1
Journal	Clinical Lung Cancer
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.cllc.2018.10.005
Publication status	Published - Mar 2019

Keywords

Advanced stage
Induction therapy
Lung cancer
Short and long term outcomes
Surgery

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2018.10.005

Cite this

@article{51cc1ef8c4ce4d72b0acea4a1fc204e2,

title = "Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?",

abstract = "This study aims to analyze the outcome of patients with stage IIIA-N2 non–small-cell lung cancer who underwent pneumonectomy to prove its safety and feasibility, in particular after induction chemotherapy. Based on the acceptable morbidity and mortality rate and the long-term survival, pneumonectomy should not be excluded for selected patients as a matter of principle.",

keywords = "Advanced stage, Induction therapy, Lung cancer, Short and long term outcomes, Surgery",

author = "Monica Casiraghi and Juliana Guarize and Alberto Sandri and Patrick Maisonneuve and Daniela Brambilla and Rosalia Romano and Domenico Galetta and Francesco Petrella and Roberto Gasparri and Cesare Gridelli and {De Marinis}, Filippo and Lorenzo Spaggiari",

year = "2019",

month = mar,

doi = "10.1016/j.cllc.2018.10.005",

language = "English",

volume = "20",

pages = "97--106.e1",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Pneumonectomy in Stage IIIA-N2 NSCLC

T2 - Should It Be Considered After Neoadjuvant Chemotherapy?

AU - Casiraghi, Monica

AU - Guarize, Juliana

AU - Sandri, Alberto

AU - Maisonneuve, Patrick

AU - Brambilla, Daniela

AU - Romano, Rosalia

AU - Galetta, Domenico

AU - Petrella, Francesco

AU - Gasparri, Roberto

AU - Gridelli, Cesare

AU - De Marinis, Filippo

AU - Spaggiari, Lorenzo

PY - 2019/3

Y1 - 2019/3

N2 - This study aims to analyze the outcome of patients with stage IIIA-N2 non–small-cell lung cancer who underwent pneumonectomy to prove its safety and feasibility, in particular after induction chemotherapy. Based on the acceptable morbidity and mortality rate and the long-term survival, pneumonectomy should not be excluded for selected patients as a matter of principle.

AB - This study aims to analyze the outcome of patients with stage IIIA-N2 non–small-cell lung cancer who underwent pneumonectomy to prove its safety and feasibility, in particular after induction chemotherapy. Based on the acceptable morbidity and mortality rate and the long-term survival, pneumonectomy should not be excluded for selected patients as a matter of principle.

KW - Advanced stage

KW - Induction therapy

KW - Lung cancer

KW - Short and long term outcomes

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85056323561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056323561&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.10.005

DO - 10.1016/j.cllc.2018.10.005

M3 - Article

C2 - 30446406

AN - SCOPUS:85056323561

VL - 20

SP - 97-106.e1

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -

Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this